<DOC>
	<DOCNO>NCT00252122</DOCNO>
	<brief_summary>The purpose pilot study provide preliminary assessment feasibility efficacy intravenous ketamine control pain patient sickle cell disease ( admitted hospital severe , acute pain crisis , resistant intravenous narcotic ) .</brief_summary>
	<brief_title>Pilot Study Effects Intravenous Ketamine Acute Pain Crisis Patients With Sickle Cell Disease</brief_title>
	<detailed_description>It often difficult manage acute painful crisis patient sickle cell disease . The usual management crisis rely hydration , administration oxygen narcotic , like morphine . A select group patient , unknown reason , respond management patient often require prolong use ( several day ) intravenous narcotic . Narcotics proven ineffective control type pain cause multiple side effect ( sedation , vomit , respiratory depression ) . We propose administer intravenous ketamine group patient resistant intravenous narcotic . Ketamine proven effective control pain multiple clinical situation . However , data literature describing use patient sickle cell disease .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Children age 7 &lt; 19 Acute vasoocclusive crisis Persistent pain despite initial pain management intravenous ( IV ) opioids Contraindications use ketamine Mental retardation psychological condition may affect proper evaluation pain side effect Known allergy ketamine</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>